| B43 | Immediate versus delayed antiretroviral treatment in hospitalized persons with AIDS-defining opportunistic disease: a randomized clinical trial | E-poster | New strategies (2DR, rapid start) |
| B43 | Largely increasing amounts of patients under dual ART due to new therapeutic regimens: dual therapy regimens 2016-2020 in the German North Rhine Cohort | E-poster | New strategies (2DR, rapid start) |
| B43 | Feasibility, efficacy, and safety of Dolutegravir/Lamivudine (DTG/3TC) as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV (PLWH): 48-week results of the STAT study | E-poster | New strategies (2DR, rapid start) |
| B43 | 48 weeks efficacy and tolerability of dolutegravir (DTG) + lamivudine (3TC) in adult HIV naïve patients. A multicenter real life cohort | E-poster | New strategies (2DR, rapid start) |
| B43 | Immediate ART is feasible during the COVID-19 pandemic | E-poster | New strategies (2DR, rapid start) |
| B42 | Region-specific laboratory reference intervals are important: a review of the data from Africa | E-poster | Ethical issues in clinical trials and treatment strategies |
| B40 | Self-reported antiretroviral adherence: association with maternal viral load suppression in HIV-1-infected postpartum women in Promoting Maternal and Infant Survival Everywhere (PROMISE): randomized, open label trial in sub-Saharan Africa and India | E-poster | Adherence measurement |
| B40 | Estimating minimum adherence required for plasma HIV-1 RNA viral load suppression among people who use unregulated drugs in Vancouver, Canada | E-poster | Adherence measurement |
| B40 | Utilization of antiretroviral refill histories as a predictor of future HIV viremia | E-poster | Adherence measurement |
| B4 | Increased ability of the new lateral flow point-of-care HIV-Combo test to detect acute HIV infection in Eswatini | E-poster | HIV testing and retesting |